Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens

Cell Death and Disease

Volumn 3, Issue 11, 2012, Pages

  Anvekar, R A ^a,b,c   Asciolla, J J ^a,b,c   Lopez Rivera, E ^a,b   Floros, K V ^a,c   Izadmehr, S ^b   Elkholi, R ^a,c   Belbin, G ^a,b,c   Sikora, A G ^a,b,c   Chipuk, J E ^a,b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Department of Dermatology ^*  (United States)

^c Tisch Cancer Institute   (United States)

Author keywords

ABT 737; Apoptosis; BCL 2 family; Chemotherapy; Melanoma

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BIM PROTEIN; CISPLATIN; DACARBAZINE; PHOSPHATIDYLSERINE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; VINBLASTINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MELANOMA; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; HUMANS; MELANOMA; MITOCHONDRIA; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 84870492761     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.161     Document Type: Article

References (25)

1. Ibrahim N, Haluska FG. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 2009; 4: 551-579.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
3. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008; 8: 121-132.
4. Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 2008; 18: 157-164.
5. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37: 299-310.
6. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 2002; 111: 331-342.
7. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183-192.
8. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525-535.
9. Chipuk JE, Fisher JC, Dillon CP, Kriwacki RW, Kuwana T, Green DR et al. Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci USA 2008; 105: 20327-20332.
10. Hocker TL, Singh MK, Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 2008; 128: 2575-2595.
11. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277-288.
12. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-283.
13. Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996; 7: 827-835.
14. Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989; 64: 2024-2029.
15. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19: 3477-3482.
16. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351: 998-1012.
17. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
18. Elkholi R, Floros KV, Chipuk JE. The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment. Genes Cancer 2011; 2: 523-537.
19. Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 1975; 35: 218-224.
20. Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Curr Protoc Immunol 2001 Chapter 20: Unit 20 21.
21. Anvekar RA, Asciolla JJ, Missert DJ, Chipuk JE. Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment. Front Oncol 2011; 34: 1-16.
22. Hagedorn M, Javerzat S, Gilges D, Meyre A, de Lafarge B, Eichmann A et al. Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci USA 2005; 102: 1643-1648.
23. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
24. Logue SE, Elgendy M, Martin SJ. Expression, purification and use of recombinant annexin V for the detection of apoptotic cells. Nat Protoc 2009; 4: 1383-1395.
25. Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 1988; 107: 2437-2445